“Vista’s View – A Weekly FREE Market Update 12-8-18″…Now Available!

Vista Partners has published “Vista’s View – A Weekly Market Update Newsletter 12-8-18!”  

Each weekly newsletter is written by Vista Partners’ Managing Director, John Heerdink.   Vista’s View includes an exclusive view on the stock market for the week, a “Stocks To Watch” section, featured stories that span from the Dow 30, select emerging growth companies, investing basics & exciting videos from Vista’s Coverage Universe and beyond.

Vista Covers all Dow 30 components, International Companies, Select Emerging Growth Companies & more on the website daily.

 Download the latest Exclusive FREE Newsletter at the Vista Partners’ Newsletters Page Now.  It’s FREE!!!

Stay Informed! Stay Competitive!  Receive our FREE email updates by signing up today in just  few seconds!

 

 

 

 

 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.




“Contrasts” – Vista Partners Daily Market Recap 12/7/2018

Several contrasts emerged on Friday, the first being between plunging stocks and soaring oil prices after OPEC agreed to slash its output by 1.2 million barrels per day. After opening with gains, stocks quickly slid with the S&P 500 ending down 2.33% (62.87 points) and the Nasdaq falling 3.05% (219.01 points). The Dow also performed poorly, as it plummeted 2.24% to end the session.

Individually, components of the Dow were down across the board, with every company in the index reporting losses. Intel (INTC) suffered the worst losses as it saw shares decrease 4.40%. Cisco (CSCO) wasn’t too far behind with a fall of 4.03%, and Microsoft (MSFT) rounded out the bottom three as it tumble 4.00%.

Atossa Genetics (ATOS) managed to buck the trend and end the day with gains of 1.54%.

An investment in the leveraged vehicle,  VelocityShares Daily 2x VIX ST ETN (TVIX) or the TVIX a many call it, produced another amazing day with a 14.70% increase on Friday!

The second contrast apparent today was between the volatility of the markets and the generally solid economic data. The jobs report for November showed that job growth was positive for the month but under economists’ predictions, and it showed that unemployment had held steady at 3.7%.

Paul Ashworth of Capital Economics had this to say about the apparent contrast. “The slightly more modest 155,000 gain…is still a solid gain that suggests economic growth is gradually slowing back toward its potential pace. There is nothing here to suggest the economy is suffering a more sudden downturn.”

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Sign Up to receive FREE email updates here!

Stocks tumble, crude oil surges on OPEC deal

Stock got slammed on Friday, and crude oil surged on an OPEC deal…

finance.yahoo.com

Read Full Article



“Free Falling” – Vista Partners Daily Market Recap 12/4/2018

After a strong showing yesterday, the market was in a free fall on Tuesday as stocks went crashing. The S&P 500 shed 3.24% during today’s session while the Nasdaq plummeted 3.80%. The Dow plunged 3.10% as the market closed.

Individual components of the Dow were down across the board, with every single company ending the day in the red. Caterpillar (CAT) led declines with a loss of 6.93%. Other companies seeing heavy losses include Boeing (BA), with a drop of 4.85%, and Intel (INTC), which sank 4.75%.

Outside the Dow, Atossa Genetics (ATOS) didn’t fare much better. It dropped 2.90% during today’s session after impressive gains yesterday.

On the other side of the coin a bet, trade on investment in the VelocityShares Daily 2x VIX ST ETN (TVIX), a “bet against the broad markets,” paid off handsomely today as it closed at $44.47 up +25.13% on the day! Thank you triggered algorythmic trades!

Two major factors are being blamed for today’s sudden downturn. The first was yesterday’s inversion of the 3-year and 5-year notes, a warning sign pointing to a possible recession. This was the first inversion since 2007 and served to spook already wary investors.

The second factor was the contradictions from the White House on the exact nature of the trade deal with China that President Trump had touted this weekend. These differing reports led many to believe that the deal may not be as solid as the president had made it seem. Basically fear crept back into the markets prior to tomorrow’s closure of the markets in honor of George H. W. Bush.

Jim Tierney, with Alliance Bernstein sees a very bleak future as quite possible if Trump isn’t able to assure investor’s that the trade tensions are under control. “If we have a trade problem, I think that risks bringing a number of developing economies to the brink of recession. It also puts a huge tax of U.S. consumers, and the combination of those two means a pretty meaningful global slowdown, which would indicate that right now the yield curve is correct in terms of where we’re going,” Tierney noted.

One might also point to the selloff being due in part to the unsettling nature of a Wednesday market closing with all outstanding aforementioned issues directly related to the US unresolved and the worldwide issue of the Brexit situation. The fear surrounding the market was too much for many to handle…understandably so.

Tomorrow will provide a break from today’s turmoil as the market is closing in honor of deceased President George H.W. Bush’s funeral. Rest in peace President Bush.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Sign Up to receive FREE email updates here!

Stocks nosedive, Dow sheds nearly 800 points

Stocks tanked Tuesday as a slew of concerns over trade tensions and an inversion in part of the U.S. yield curve spooked investors…

finance.yahoo.com

Read Full Article



Markets React Well to Atossa Genetics (ATOS) Announcing FDA Approval For “Expanded Access”

Atossa Genetics Inc., (NasdaqCM; ATOS) is a Seattle-based clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. ATOS announced on Monday that the FDA has approved an “expanded access” of Atossa’s proprietary oral Endoxifen in the preoperative setting in a U.S. patient awaiting surgery for breast cancer. Under the FDA Expanded Access IND program, the use of Atossa’s proprietary Endoxifen is restricted to this patient only.

The markets reacted positively to this news on Monday as ATOS shot up over 50% and hit a high of $1.85 while trading north of 16.8 million shares or approximately $28-30 million dollars of trading before closing at $1.38.

Note that Atossa is currently conducting a Phase 2 study of its oral Endoxifen in Australia in the “window of opportunity” between diagnosis of breast cancer and surgery.  Steven C. Quay, Ph.D., MD, President and CEO stated. “Once a patient is diagnosed with breast cancer, there is a window of time, typically a few weeks, before surgery is performed. Our goal with this study is to show that our proprietary oral Endoxifen can modify the cancer activity in ER+ breast cancer during this ‘window of opportunity.’ Because our Phase 1 study indicated that our oral Endoxifen reaches therapeutic levels within 8 hours and therapeutic steady-state levels in only seven days, we are optimistic we can achieve a valuable treatment effect.”

The Pilot Phase of the study will initially enroll up to eight newly-diagnosed patients with ER+ and HER2 negative (HER2-) stage 1 or 2 invasive breast cancer, requiring mastectomy or lumpectomy. Patients will receive Atossa’s proprietary oral Endoxifen for at least 21 days from the time of diagnosis up to the day of surgery. Provided tumor activity reduction is demonstrated in at least two patients, an additional 17 patients will be enrolled for a total of 25. The primary endpoint is to determine if the administration of oral Endoxifen reduces the tumor activity as measured by Ki-67, which is a marker of cellular proliferation. The secondary endpoints are safety and tolerability and assessment of the study drug on expression levels of both estrogen and progesterone receptors. The impact on additional markers of cellular activity will also be explored. The Phase 2 study is being conducted on behalf of Atossa by CPR Pharma Services Pty Ltd., Thebarton, SA, Australia. CPR Pharma recently completed the successful Phase 1 study of Atossa’s oral and topical Endoxifen in women.

Steven C. Quay, Ph.D., MD, President and CEO commented further, “A physician recently contacted Atossa and requested our proprietary oral Endoxifen for a pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient awaiting surgery. In this setting, the recommended preoperative endocrine systemic therapy is typically an aromatase inhibitor and a drug for ovarian suppression. The patient’s physician was reluctant to use this preoperative therapy as it typically induces menopause and can have other potentially serious side effects. We worked with the physician to apply to the FDA to provide “expanded access” (formerly known as compassionate use) to this patient under an Investigational New Drug (IND) application. We are very pleased to report that the FDA approved this single-patient study, and the patient is currently receiving our proprietary oral Endoxifen preoperatively. This is the same clinical setting as our Phase 2 ‘window of opportunity’ study of preoperative systemic oral Endoxifen in breast cancer patients which is open for enrollment in Australia.”

Note that expanded access, sometimes called “compassionate use, is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available. Expanded access may be appropriate when all the following apply: patient has a serious disease or condition, or whose life is immediately threatened by their disease or condition; there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; patient enrollment in a clinical trial is not possible; potential patient benefit justifies the potential risks of treatment; providing the investigational medical product will not interfere with investigational trials that could support a medical product’s development or marketing approval for the treatment indication. Investigational drugs, biologics or medical devices have not yet been approved or cleared by FDA and FDA has not found these products to be safe and effective for their specific use. Furthermore, the investigational medical product may, or may not, be effective in the treatment of the condition, and use of the product may cause unexpected serious side effects. For more information, see the FDA website: FDA Expanded Use Website

If you found this story interesting you should consider following Atossa Genetics (Nasdaq: ATOS)  please see Atossa the dedicated coverage page at Vista Partners to learn more.

Atossa Genetics Announces FDA Approval of Endoxifen for “Expanded Access” as Preoperative Systemic Endocrine Therapy for a U.S. Breast Cancer Patient

Steven C. Quay, Ph.D., MD, President and CEO commented, “A physician recently contacted Atossa and requested our proprietary oral Endoxifen for a pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient awaiting surgery. In this setting, the recommended preoperative endocrine systemic..

finance.yahoo.com

Read Full Article



“The Good & The Bad” – Vista Partners Daily Market Recap 12/3/2018

The good news is that stocks rallied on Monday as investors optimistic about reduced trade tensions with China after President Trump announced a 90-day cease fire in the trade war as negotiations continue. S&P 500 ended the session up 1.09% and the Nasdaq rose 1.51%. The Dow closed out the day with gains of 1.13%.

Most individual components of the Dow did well today, although some did dip into the red. Of those companies with losses, Verizon (VZ) had the most significant as it tumbled 3.55%. Boeing (BA) led the day with gains, rising 3.81%, and NIKE (NKE) wasn’t far behind with an increase of 3.75%

Atossa Genetics (ATOS) had a VERY good day as it saw shares spike 21.05% into the close on over 16.8 million shares of trading after hitting intraday highs that pushed the stock up over 50% at times. Note that ATOS is a Seattle based clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. The action in ATOS surfaced after the they announced that the FDA had approved an “expanded access” of Atossa’s proprietary oral Endoxifen in the preoperative setting in a U.S. patient awaiting surgery for breast cancer.

The bad news for the markets today though, came from an ominous sign in the bond market. For the first time since 2007, there was an inversion in Treasury yields. This inversion is a tell-tale sign that the market is typically headed toward recession and that there is a greater risk of the government defaulting.

While the major inversion that analysts look for to herald a recession is between the 2-year and 10-year yields, today’s was between the 3-year and 5-year yields.

Ian Lyngen, with BMO Captial Markets, stated that today’s inversion gives him even more reason to believe that there will be an inversion of the 2-year and 10-year yields late this year or in the early part of next year. According to Lyngen, “This solidifies not only my flattening bias but I think it will lead many players in the market who [expected the yield curve to steepen] to capitulate on that.”

Another negative sign came as U.S. construction spending was reported to have decreased by 0.1% in October. This is the 3rd consecutive month of decreases for construction spending in the U.S.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Stocks give up some gains after trade talk advances

Stocks pared some gains after optimism for a trade war truce between the U.S. and China had sent equities soaring earlier during Monday’s session…

finance.yahoo.com

Read Full Article



Worldwide Entertainment Company Disney Announces Semi-Annual Cash Dividend

Dow 30 Component, The Walt Disney Company (DIS),  and its subsidiaries is a diversified worldwide entertainment company that operates in four business segments: Studio Entertainment, Media Networks, Parks and Resorts, and Consumer Products & Interactive Media.

The Walt Disney Company Board of Directors has declared a semi-annual cash dividend of $0.88 per share. The dividend will be payable on January 10, 2019, to those shareholders of record on December 10, 2018, at the close of business.

The previous semi-annual dividend was declared at $0.84 per share in July.

Along with the declaration of the semi-annual dividend, Disney also announced that it has scheduled its annual shareholders’ meeting for March 7, 2019. The meeting will take place in St. Louis, MO.

To learn more about this Dow 30 Component, The Walt Disney Company (DIS), and to continue to track its progress please visit the Vista Partners Walt Disney Company Coverage Page.

Shallow Focus Photo Of Dry Leaves

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.

The Walt Disney Company Announces Semi-Annual Cash Dividend of $0.88 Per Share – The Walt Disney Company

..

www.thewaltdisneycompany.com

Read Full Article



Will the Coca-Cola Santa Be on Your Holiday Cards this Season?

Dow 30 Component, The Coca-Cola Company (KO), is the largest total beverage company in the world. It offers 500 plus brands in over 200 countries and is committed to reducing sugar in its drinks and providing new and diverse drinks to people everywhere.

Be on the look out for Coca-Cola holiday stamps this year as you send out your holiday cards. The U.S. Postal Service is currently offering a series of holiday stand that feature Santa Claus images done by the artist Haddon Sundblom for the Coca-Cola ads from the 1940’s to 1960’s.

The Forever stamps are being sold in booklets of 20 and feature four timeless portraits of jolly old St. Nick that show the progression of the Coca-Cola Santa. This is Coca-Cola’s first ever collaboration with the Postal Service and has been in the works for the past three years.

Making its first appearance in 1931 as an ad campaign in the Saturday Evening Post, the popular Coca-Cola Santa continued to appear each season which enforced a consistent look for Santa that reflected the times. With over 40 original oil painting of Santa created by Sundblom, the “Coca-Cola Santa” became the standard recognition of Saint Nick.

Coca-Cola didn’t invent Santa Claus, but we did – with Sundblom – help shape how people around the world see him. Coca-Cola and Santa each continue to be associated with the holiday season, representing unwavering symbols of happiness and hope passed down from generation to generation.” – Justine Fletcher, director of Heritage Communications at The Coca-Cola Company

Sundblom’s ‘Coca-Cola Santa’ Gets Its Own Commemorative Stamp

The U.S. Postal Service has released a series of commemorative holiday stamps featuring Santa Claus images painted by artist Haddon Sundblom for Coca-Cola Christmas ads from the 1940s through the early 1960s.

..

www.coca-colacompany.com

Read Full Article



Dow 30 Component Cisco Will Participate In Multiple Conferences Throughout December

Cisco Systems, Inc. (CSCO) is a global technology leader that designs, manufactures, and sells Internet Protocol-based networking and other communications technology.

Cisco has a busy month in the financial community, participating in multiple conferences throughout December. All sessions will be available via webcast through the company’s investor relations website investor.cisco.com for anyone interested.

Cisco will be participating in the following conferences:

Wells Fargo Tech Summit –December 4, 2018
2:20 p.m. MT / 4:20 p.m. ET
Park City, UT
Ish Limkakeng, SVP, Product Management, Data Center Business Group

Nasdaq 39th Investor Conference -December 5, 2018
8:45 a.m. GMT / 3:45 a.m. ET
London, UK
Kelly Kramer, EVP, Chief Financial Officer

Barclays Global Technology, Media and Telecommunications Conference -December 6, 2018
11:00 a.m. PT / 2:00 p.m. ET
San Francisco, CA
David Goeckeler, Executive VP and General Manager, Networking and Security Business

Cowen Security and Networking Conference -December 11, 2018
Onsite 1×1 meetings only
New York, NY
Kip Compton, SVP, Cloud Platform and Solutions Group

To learn more about Cisco Systems, Inc. (CSCO) and to continue to track its progress please visit the Vista Partners Cisco Systems, Inc. Coverage Page.

Man Wearing Blue T-shirt Riding Bicycle on Street

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.

Cisco Announces December 2018 Events with the Financial Community

..

investor.cisco.com

Read Full Article



Apple Seeks Women Entrepreneurs for New Development Program

Dow 30 component Apple (AAPL) revolutionized personal technology with the introduction of the Macintosh in 1984. Today Apple leads the world in innovation with iPhone, iPad, Mac, Apple Watch and Apple TV. Apple’s four software platforms — iOS, macOS, watchOS, and tvOS — provide seamless experiences across all Apple devices and empower people with breakthrough services including the App Store, Apple Music, Apple Pay and iCloud. Apple’s more than 100,000 employees are dedicated to making the best products on earth, and to “leaving the world better than they found it.”

Apple recently announced the launch of its brand new Entrepreneur Camp. The camp is designed to create new opportunities for app-driven businesses owned or led by women. It features an intensive technology lab, specialized support, and ongoing mentoring.

Those eligible for the program, the business must be female-founded, co-founded, or led and there must be one woman on the development team along with a working app or prototype and desire to use Apple technologies in the business.

The women-focused program will begin in January 2019 and is currently accepting applications. The camp will hold quarterly sessions, each round will have 20 companies accepted and the pilot round will have 10 companies.

Upon acceptance into the program, each company will be allowed to send three representatives to Cupertino, California for a two week long, enveloping program at the Apple campus. The program will include sessions on coding, design, technology, App Store marketing, and guidance and support from an Apple Developer representative.

More information on the Entrepreneur Camp and program applications can be found at developer.apple.com/entrepreneur-camp.

Learn more about Apple and track its ongoing progress at Vista Partners Apple (AAPL) Coverage Page.

Woman With Blonde Hair at the Top of the Mountain Raising Her Hands

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.

Apple launches app development program to support women entrepreneurs

..

www.apple.com

Read Full Article



“Vista’s View – A Weekly FREE Market Update 12-1-18″…Now Available!

Vista Partners has published “Vista’s View – A Weekly Market Update Newsletter 12-1-18!”  Each weekly newsletter is written by Vista Partners’ Managing Director, John Heerdink.   Vista’s View includes an exclusive view on the stock market for the week, a “Stocks To Watch” section, featured stories that span from the Dow 30, select emerging growth companies, investing basics & exciting videos from Vista’s Coverage Universe and beyond.

Vista Covers all Dow 30 components, International Companies, Select Emerging Growth Companies & more on the website daily.

 Download the latest Exclusive FREE Newsletter at the Vista Partners’ Newsletters Page Now.  It’s FREE!!!

Stay Informed! Stay Competitive!  Receive our FREE emial updates by signing up today in just  few seconds!

 

 

 

 

 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.